title: To overcome pharmacologic and cytokinetic resistance to cytarabine in the treatment of acute myelogenous leukemia by using recombinant interleukin-3?
authors.affiliation: Department of Hematology and Oncology, University of Freiburg Medical Center, Germany.
authors.forename: M A
authors.initials: MA
authors.lastname: Brach
authors.forename: R
authors.initials: R
authors.lastname: Henschler
authors.forename: R
authors.initials: R
authors.lastname: Mertelsmann
authors.forename: F
authors.initials: F
authors.lastname: Herrmann
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D002453:Cell Cycle / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D003561:Cytarabine / Q000494:pharmacology / Q000627:therapeutic use*; D004351:Drug Resistance; D006801:Humans; D007377:Interleukin-3 / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D007377:Interleukin-3; D011994:Recombinant Proteins; D003561:Cytarabine